Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 368681, 11 pages
http://dx.doi.org/10.1155/2014/368681
Research Article

Prediction of Methotrexate Clinical Response in Portuguese Rheumatoid Arthritis Patients: Implication of MTHFR rs1801133 and ATIC rs4673993 Polymorphisms

1CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Pharmaceutical Sciences, Higher Institute of Health Sciences (ISCS-N), Rua Central de Gandra 1317, 4585-116 Gandra PRD, Portugal
2Molecular Oncology Group CI, Portuguese Institute of Oncology of Porto (IPO-Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal
3Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
4Faculty of Medicine of University of Porto (FMUP), Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
5Rheumatology Department, São João Hospital Center, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
6Virology Service, Portuguese Institute of Oncology of Porto (IPO-Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal
7Research Department-Portuguese League Against Cancer (LPCC-NRNorte), Estrada Interior da Circunvalação 6657, 4200-177 Porto, Portugal

Received 28 February 2014; Revised 22 April 2014; Accepted 22 April 2014; Published 21 May 2014

Academic Editor: Miguel A. González-Gay

Copyright © 2014 Aurea Lima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [20 citations]

The following is the list of published articles that have cited the current article.

  • Vasco C. Romão, Aurea Lima, Miguel Bernardes, Helena Canhão, and João Eurico Fonseca, “Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?,” Immunologic Research, vol. 60, no. 2-3, pp. 289–310, 2014. View at Publisher · View at Google Scholar
  • Aurea Lima, Miguel Bernardes, Rita Azevedo, Rui Medeiros, and Vitor Seabra, “Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?,” International Journal Of Molecular Sciences, vol. 16, no. 6, pp. 13760–13780, 2015. View at Publisher · View at Google Scholar
  • Tomas Soukup, Tomas Veleta, Jiri Vlcek, Martin Dosedel, Petr Pavek, Jana Nekvindova, Ivan Barvik, Iva Bubancova, Petr Bradna, Ales Antonin Kubena, and Alejandro Fernández Carazo, “The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients,” Rheumatology International, vol. 35, no. 7, pp. 1149–1161, 2015. View at Publisher · View at Google Scholar
  • Aurea Lima, Miguel Bernardes, Rita Azevedo, Vitor Seabra, and Rui Medeiros, “Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome,” Pharmacogenomics, 2016. View at Publisher · View at Google Scholar
  • Cătălin Codreanu, Horațiu Popovici, Magda Pârvu, Daniela Opriș, Corina Mogoșan, Claudiu Costinel Popescu, Simona Rednic, and Ruxandra Ionescu, “Pre-treatment antinuclear antibody positivity, therapeutic efficacy and persistence of biologics in rheumatoid arthritis,” Revista Romana de Medicina de Laborator, vol. 24, no. 2, pp. 213–223, 2016. View at Publisher · View at Google Scholar
  • Niveditha Muralidharan, Christina M Mariaselvam, Vikramraj K Jain, Reena Gulati, and Vir S Negi, “ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis,” Pharmacogenomics, vol. 17, no. 3, pp. 241–248, 2016. View at Publisher · View at Google Scholar
  • Damian Malinowski, Natalia Szarmach, Mateusz Kurzawski, Anna Nowak, Aleksandra Goryniak, Andrzej Pawlik, and Marek Droździk, “ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients,” Pharmacogenomics, vol. 17, no. 18, pp. 1971–1978, 2016. View at Publisher · View at Google Scholar
  • Tomas Soukup, Jana Nekvindova, Martin Dosedel, Jindra Brtkova, Jan Toms, Drahomira Bastecka, Petr Bradna, Jiri Vlcek, and Petr Pavek, “Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins,” International Journal of Immunopathology and Pharmacology, vol. 29, no. 4, pp. 790–795, 2016. View at Publisher · View at Google Scholar
  • Maciej Tarnowski, Agnieszka Paradowska-Gorycka, Ewa Dąbrowska-Zamojcin, Michal Czerewaty, Sylwia Słuczanowska-Głąbowska, and Andrzej Pawlik, “The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy,” Expert Opinion on Drug Metabolism and Toxicology, vol. 12, no. 1, pp. 41–54, 2016. View at Publisher · View at Google Scholar
  • Goran Radunovic, Tatjana Damnjanovic, Nemanja Damjanov, Dubravka Vejnovic, Sofija Pavkovic-Lucic, Biljana Jekic, Vera Milic, Nela Maksimovic, Vera Bunjevacki, Ljiljana Lukovic, Ivana Novakovic, and Maja Krajinovic, “Analysis of association between polymorphisms of MTHFR, MTHFD1 and RFC1 genes and efficacy and toxicity of methotrexate in rheumatoid arthritis patients,” Genetika, vol. 48, no. 1, pp. 395–408, 2016. View at Publisher · View at Google Scholar
  • Wenjing Shao, Yi Yuan, and Yuying Li, “ Association Between MTHFR C677T Polymorphism and Methotrexate Treatment Outcome in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis ,” Genetic Testing and Molecular Biomarkers, 2017. View at Publisher · View at Google Scholar
  • Qi Qiu, Jing Huang, Xiaoming Shu, Huizheng Fan, Youwen Zhou, and Cheng Xiao, “Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.,” Scientific reports, vol. 7, pp. 44015, 2017. View at Publisher · View at Google Scholar
  • Wefa Boughrara, Ahmed Benzaoui, Meriem Aberkane, Fatima Zohra Moghtit, Samia Dorgham, Aicha sarah Lardjam-Hetraf, Hadjer Ouhaibi-Djellouli, Elisabeth Petit Teixeira, and Abdallah Boudjema, “No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population,” Inflammation Research, vol. 66, no. 6, pp. 505–513, 2017. View at Publisher · View at Google Scholar
  • Jenko, Lusa, Tomsic, Praprotnik, and Dolzan, “Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis,” Pharmacogenomics Journal, vol. 17, no. 5, pp. 412–418, 2017. View at Publisher · View at Google Scholar
  • Kun Zou, Yuan Yang, Gang Liu, Yuehong Chen, and Jianhong Sun, “Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis,” Pharmacogenomics, vol. 18, no. 2, pp. 175–195, 2017. View at Publisher · View at Google Scholar
  • Kimme L. Hyrich, James Anderson, Kamilla Kopec-Harding, Holly F. Hope, Deborah P.M. Symmons, Suzanne M.M. Verstappen, Jamie C. Sergeant, and Anne Barton, “Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: Results from the UK Rheumatoid Arthritis Medication Study (RAMS),” Arthritis Research and Therapy, vol. 20, no. 1, 2018. View at Publisher · View at Google Scholar
  • Marco Colombo, Peter Orchard, Jackie L. Nam, Heather J. Cordell, John D. Isaacs, Tim Bongartz, Donna Arnett, Paul P. Tak, S. Louis Bridges, Suzanne M. M. Verstappen, Jonathan Massey, Felix Agakov, Richard Weinshilboum, Ann W. Morgan, Athina Spiliopoulou, Jianmei Wang, John C. Taylor, Sarah Twigg, Iain B. McInnes, Duncan Porter, Jane E. Freeston, Jenna L. Strathdee, Maria J. H. de Hair, Stella Aslibekyan, Ronald F. van Vollenhoven, Leonid Padyukov, Costantino Pitzalis, Andrew P. Cope, Paul Emery, Michael R. Barnes, Paul McKeigue, Taisei Mushiroda, Michiaki Kubo, Anne Barton, Jennifer H. Barrett, Borbala Mifsud, Ian C. Scott, Michael Morgan, and Darren Plant, “Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients,” Pharmacogenomics Journal, vol. 18, no. 4, pp. 528–538, 2018. View at Publisher · View at Google Scholar
  • Rosario López-Rodríguez, Aida Ferreiro-Iglesias, Aurea Lima, Miguel Bernardes, Andrzej Pawlik, Agnieszka Paradowska-Gorycka, Jerzy Świerkot, Ryszard Slezak, Vita Dolžan, Isidoro González-Álvaro, Javier Narváez, Rafael Cáliz, Eva Pérez-Pampín, Antonio Mera-Varela, Laura Vidal-Bralo, José Gorgonio Acuña Ochoa, Carmen Conde, Juan J. Gómez-Reino, and Antonio González, “Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis,” Scientific Reports, vol. 8, no. 1, 2018. View at Publisher · View at Google Scholar
  • Tomas Soukup, Tomas Veleta, Jurjen Duintjer Tebbens, Petr Pavek, Martin Dosedel, Ivan Barvik, Jana Nekvindova, and Ales A Kubena, “Are haplotypes in a single methotrexate pathway more predictive for response in rheumatoid arthritis than in different pathways?,” Pharmacogenomics, vol. 19, no. 5, pp. 379–381, 2018. View at Publisher · View at Google Scholar
  • Barbara Jenko, Matija Tomšič, Biljana Jekić, Vera Milić, Vita Dolžan, and Sonja Praprotnik, “Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models,” Frontiers in Pharmacology, vol. 9, 2018. View at Publisher · View at Google Scholar